Allison Wey, VP of IR for Durata Therapeutics through its acquisition by Actavis, has moved to Regulus Therapeutics as VP of IR and corporate communications.
COO Jay Hagan said Wey's experience will be valuable as the publicly traded company's pipeline matures. Regulus is focused on microRNA therapeutics and developing treatments for chronic hepatitis C virus and Alport syndrome, among others.
Earlier, she was VP of IR and corporate affairs at Par Pharmaceuticals, departing on its acquisition by TPG. She was also VP of IR for Boren.
On the agency side, Wey was a senior VP at Edelman Financial and managing director for financial communications at Hill+Knowlton Strategies after starting out in finance.
Established through a founding gift from 2025 Page Hall of Fame inductee and former Weber Shandwick Global CEO Andy Polansky, the fund is meant to serve as a catalyst for empowering future senior communications leaders as well as increasing the diversity in the chief communications officer pipeline.
Some well-honed communications strategies typically deployed in an activist situation must be set aside when the activist is also the founder of the company. Such situations require a more tailored response: one that respects the founder’s credibility without conceding the company’s future, addresses shareholders’ financial interests while acknowledging questions of legacy, and anticipates that the fight may be as personal and persistent as it is strategic.
Molly Fogarty, who rose to head of corporate affairs & sustainability at Nestle during a nearly 23-year stint, will join Brunswick Group as a partner in DC on Sept. 14.
Senior leaders have been exiting newly combined agencies since the wave of integrations started—the kind of departures that don't always make headlines but show up in who's running client accounts six months later.
Why CEO visibility is no longer optional as a communications tactic.
